$AIDX
20/20 Biolabs, Inc.
Nasdaq · Services · Services-Testing Laboratories · Rockville, MD
AIDX chart
What traders are saying about $AIDX
Latest posts20/20 Biolabs, Inc. news
- 20/20 Biolabs (NASDAQ:AIDX) Penny Stock: Shares Trade Below Cash After a Month of Declines
kalkine.ca ·
- 20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
Yahoo Finance ·
- 20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
Yahoo Finance ·
- Profound Medical Stock And 2 Canadian AI Healthcare Stocks To Watch
Yahoo Finance ·
- Healwell AI (TSX:AIDX) Stock Draws Fresh Price Target Split After Quarterly Results
Yahoo Finance ·
- 20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
Yahoo Finance ·
- 20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
Yahoo Finance ·
- 20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
Yahoo Finance ·
- 20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
Yahoo Finance ·
- 20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
Yahoo Finance ·
- 20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock
Yahoo Finance ·
- 20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth
Yahoo Finance ·
20/20 Biolabs, Inc. key financials
| USD | 2025 | 2024 |
|---|---|---|
| Revenue | $2.0M | $1.8M |
| Net income | -$3.7M | -$5.6M |
| Diluted EPS | $-0.76 | $-1.16 |
| Total assets (year end) | $4.1M | $3.6M |
| Cash and equivalents (year end) | $1.0M | $1.8M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About 20/20 Biolabs, Inc.
- Ticker
- AIDX (Nasdaq)
- Industry
- Services-Testing Laboratories
- Headquarters
- Rockville, MD
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1139685
- Former names
- 20/20 GeneSystems, Inc., 20/20 GENE SYSTEMS INC
Frequently asked questions
What exchange is 20/20 Biolabs, Inc. listed on?
20/20 Biolabs, Inc. trades on the Nasdaq under the ticker symbol AIDX.
What industry is 20/20 Biolabs, Inc. in?
20/20 Biolabs, Inc. is classified by the SEC under "Services-Testing Laboratories", part of the Services sector on StockTweeting.
Where is 20/20 Biolabs, Inc. headquartered?
20/20 Biolabs, Inc.'s business address on file with the SEC is in Rockville, MD.
When does 20/20 Biolabs, Inc.'s fiscal year end?
20/20 Biolabs, Inc.'s fiscal year ends on December 31.
How much revenue did 20/20 Biolabs, Inc. report?
20/20 Biolabs, Inc. reported $2.0M in revenue for calendar year 2025, according to its SEC filings.